Last reviewed · How we verify
L-ornithine-L-aspartate plus latulose
L-ornithine-L-aspartate plus latulose is a Ammonia-lowering agent combination Small molecule drug developed by Qurratul Ain Jamil. It is currently FDA-approved for Hepatic encephalopathy, Portal systemic encephalopathy. Also known as: Levijon concentrate for infusion plus Duphalac.
L-ornithine-L-aspartate reduces ammonia levels by promoting its conversion to urea and glutamine, while lactulose acidifies the colon to reduce ammonia-producing bacteria and increase fecal ammonia excretion.
L-ornithine-L-aspartate reduces ammonia levels by promoting its conversion to urea and glutamine, while lactulose acidifies the colon to reduce ammonia-producing bacteria and increase fecal ammonia excretion. Used for Hepatic encephalopathy, Portal systemic encephalopathy.
At a glance
| Generic name | L-ornithine-L-aspartate plus latulose |
|---|---|
| Also known as | Levijon concentrate for infusion plus Duphalac |
| Sponsor | Qurratul Ain Jamil |
| Drug class | Ammonia-lowering agent combination |
| Modality | Small molecule |
| Therapeutic area | Hepatology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
L-ornithine-L-aspartate (LOLA) provides substrates for the urea cycle and glutamine synthesis, directly lowering blood ammonia concentrations. Lactulose acts as a non-absorbable disaccharide that lowers colonic pH, inhibits ammonia-producing bacteria, and increases fecal nitrogen excretion. Together, these agents synergistically reduce hyperammonemia and its neurological consequences.
Approved indications
- Hepatic encephalopathy
- Portal systemic encephalopathy
Common side effects
- Diarrhea
- Abdominal discomfort
- Flatulence
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-ornithine-L-aspartate plus latulose CI brief — competitive landscape report
- L-ornithine-L-aspartate plus latulose updates RSS · CI watch RSS
- Qurratul Ain Jamil portfolio CI
Frequently asked questions about L-ornithine-L-aspartate plus latulose
What is L-ornithine-L-aspartate plus latulose?
How does L-ornithine-L-aspartate plus latulose work?
What is L-ornithine-L-aspartate plus latulose used for?
Who makes L-ornithine-L-aspartate plus latulose?
Is L-ornithine-L-aspartate plus latulose also known as anything else?
What drug class is L-ornithine-L-aspartate plus latulose in?
What development phase is L-ornithine-L-aspartate plus latulose in?
What are the side effects of L-ornithine-L-aspartate plus latulose?
Related
- Drug class: All Ammonia-lowering agent combination drugs
- Manufacturer: Qurratul Ain Jamil — full pipeline
- Therapeutic area: All drugs in Hepatology / Gastroenterology
- Indication: Drugs for Hepatic encephalopathy
- Indication: Drugs for Portal systemic encephalopathy
- Also known as: Levijon concentrate for infusion plus Duphalac
- Compare: L-ornithine-L-aspartate plus latulose vs similar drugs
- Pricing: L-ornithine-L-aspartate plus latulose cost, discount & access